Last reviewed · How we verify

Hyaluronic acid and silver sulfadiazine

University of Cagliari · FDA-approved active Small molecule

Hyaluronic acid and silver sulfadiazine is a Topical wound care agent / antimicrobial dressing Small molecule drug developed by University of Cagliari. It is currently FDA-approved for Burn wounds, Chronic wounds, Surgical wounds.

Hyaluronic acid provides a moist wound healing environment while silver sulfadiazine delivers broad-spectrum antimicrobial activity to prevent infection.

Hyaluronic acid provides a moist wound healing environment while silver sulfadiazine delivers broad-spectrum antimicrobial activity to prevent infection. Used for Burn wounds, Chronic wounds, Surgical wounds.

At a glance

Generic nameHyaluronic acid and silver sulfadiazine
SponsorUniversity of Cagliari
Drug classTopical wound care agent / antimicrobial dressing
ModalitySmall molecule
Therapeutic areaDermatology / Wound Care
PhaseFDA-approved

Mechanism of action

Hyaluronic acid is a natural polysaccharide that maintains moisture at the wound site, promoting epithelialization and reducing scarring. Silver sulfadiazine is a topical antimicrobial agent that releases silver ions to inhibit bacterial growth across a wide spectrum of pathogens. Together, they create an optimal environment for wound healing while preventing secondary infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hyaluronic acid and silver sulfadiazine

What is Hyaluronic acid and silver sulfadiazine?

Hyaluronic acid and silver sulfadiazine is a Topical wound care agent / antimicrobial dressing drug developed by University of Cagliari, indicated for Burn wounds, Chronic wounds, Surgical wounds.

How does Hyaluronic acid and silver sulfadiazine work?

Hyaluronic acid provides a moist wound healing environment while silver sulfadiazine delivers broad-spectrum antimicrobial activity to prevent infection.

What is Hyaluronic acid and silver sulfadiazine used for?

Hyaluronic acid and silver sulfadiazine is indicated for Burn wounds, Chronic wounds, Surgical wounds, Traumatic wounds.

Who makes Hyaluronic acid and silver sulfadiazine?

Hyaluronic acid and silver sulfadiazine is developed and marketed by University of Cagliari (see full University of Cagliari pipeline at /company/university-of-cagliari).

What drug class is Hyaluronic acid and silver sulfadiazine in?

Hyaluronic acid and silver sulfadiazine belongs to the Topical wound care agent / antimicrobial dressing class. See all Topical wound care agent / antimicrobial dressing drugs at /class/topical-wound-care-agent-antimicrobial-dressing.

What development phase is Hyaluronic acid and silver sulfadiazine in?

Hyaluronic acid and silver sulfadiazine is FDA-approved (marketed).

What are the side effects of Hyaluronic acid and silver sulfadiazine?

Common side effects of Hyaluronic acid and silver sulfadiazine include Local irritation or sensitization, Allergic reaction to silver sulfadiazine, Discoloration of wound area.

Related